Eosinophil Proportion May Serve as a Candidate Biomarker for Adverse Events in Patients With Urothelial Carcinoma Treated With Enfortumab Vedotin.
- DOI
- 10.1002/cam4.72252
- Published
- 2026 Sep
- Container
- Cancer medicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/cam4.72252,
title = {Eosinophil Proportion May Serve as a Candidate Biomarker for Adverse Events in Patients With Urothelial Carcinoma Treated With Enfortumab Vedotin.},
author = {Odagiri K and Morikawa T and Naiki T and Sugiyama Y and Tasaki Y and Mimura Y and Naiki-Ito A and Nagai T and Etani T and Iida K and Ishikawa D and Noda Y and Shimizu N and Aoki M and Gonda M and Banno R and Kubota H and Ando R and Umemoto Y and Kawai N and Furukawa-Hibi Y and Yasui T},
year = {2026},
journal = {Cancer medicine},
doi = {10.1002/cam4.72252},
url = {https://doi.org/10.1002/cam4.72252}
}RIS
TY - JOUR TI - Eosinophil Proportion May Serve as a Candidate Biomarker for Adverse Events in Patients With Urothelial Carcinoma Treated With Enfortumab Vedotin. AU - Odagiri K AU - Morikawa T AU - Naiki T AU - Sugiyama Y AU - Tasaki Y AU - Mimura Y AU - Naiki-Ito A AU - Nagai T AU - Etani T AU - Iida K AU - Ishikawa D AU - Noda Y AU - Shimizu N AU - Aoki M AU - Gonda M AU - Banno R AU - Kubota H AU - Ando R AU - Umemoto Y AU - Kawai N AU - Furukawa-Hibi Y AU - Yasui T PY - 2026 JO - Cancer medicine DO - 10.1002/cam4.72252 UR - https://doi.org/10.1002/cam4.72252 ER -
APA
K, O., T, M., T, N., Y, S., Y, T., Y, M., A, N., T, N., T, E., K, I., D, I., Y, N., N, S., M, A., M, G., R, B., H, K., R, A., Y, U., N, K., Y, F., & T, Y. (2026). Eosinophil Proportion May Serve as a Candidate Biomarker for Adverse Events in Patients With Urothelial Carcinoma Treated With Enfortumab Vedotin.. Cancer medicine. https://doi.org/10.1002/cam4.72252
Source records
- pubmed · retrieved 2026-09-26T01:48:56.603Z
- europe-pmc · retrieved 2026-09-26T01:48:56.616Z
- doaj · retrieved 2026-09-26T01:48:56.659Z